Advertisement
Home »

PCSKP Inhibitor Achieves LDL-C Goals for Patients With High Risk for Cardiovascular Disease

Apr 26, 2024

REFERENCES & ADDITIONAL READING

Klug E. Randomized, double-blind, placebo-controlled, phase 3, study to evaluate lerodalcibep long-term efficacy and safety in patients with, or at very-high or high risk, for cardiovascular disease on stable lipid-lowering therapy. LB2, Session 405,. Presented at: ACC 2024 Scientific Session, April 6-8, 2024, Atlanta, GA.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement